Our objective was to evaluate changes in patient-reported outcome measures using the NEI-VFQ 25 questionnaire during a treat and extend regimen in naive neovascular Age-Related Macular Degeneration patients, and its correlation with anatomical and functional data. We conducted a prospective observational study. Patients underwent a treat and extend regimen with intravitreal ranibizumab for neovascular Age-Related Macular Degeneration. Initial response was evaluated at 4th month, and subsequently in every follow-up visit. If a clinical response was achieved, the injection interval was extended in two-week increments, up to a maximum of 12 weeks. Quality of life was assessed using the NEI-VFQ 25 questionnaire at baseline, 4th months, and 12th months. Patients were categorized as good or poor responders based on Best corrected visual acuity, central foveal thickness, intraretinal fluid, or subretinal fluid. Treatment with ranibizumab led to a significant improvement in quality of life, with a mean increase in NEI-VFQ 25 score of 4.27 points in the 12th month. No significant differences in improvement were observed between good and poor responders. Quality of life scores in neovascular Age-Related Macular Degeneration patients improved with intravitreal treatment regardless of the clinical response. The early response following the loading phase could indicate better quality of life after one year of treatment, with Best corrected visual acuity being the clinical parameter with the greatest influence on quality of life.
15 March 2024 in Journal of Cardiothoracic and Vascular Anesthesia
Tracheal intubation in cardiac surgery patients has a higher incidence of difficult laryngoscopic views compared with patients undergoing other types of surgery. The authors hypothesized that using the McGrath Mac videolaryngoscope as the first intubation option for cardiac surgery patients improves the percentage of patients with "easy intubation" compared with using a direct Macintosh laryngoscope. A prospective, observational, before-after study. At a tertiary-care hospital. One thousand one hundred nine patients undergoing cardiac surgery. Consecutive patients undergoing cardiac surgery were intubated using, as the first option, a Macintosh laryngoscope (preinterventional phase) or a McGrath Mac videolaryngoscope (interventional phase). The main objective was to assess whether the use of the McGrath videolaryngoscope, as the first intubation option, improves the percentage of patients with "easy intubation," defined as successful intubation on the first attempt, modified Cormack-Lehane grades of I or IIa, and the absence of the need for adjuvant airway devices. A total of 1,109 patients were included, 801 in the noninterventional phase and 308 in the interventional phase. The incidence of "easy intubation" was 93% in the interventional phase versus 78% in the noninterventional phase (p < 0.001). First-success-rate intubation was higher in the interventional phase (304/308; 98.7%) compared with the noninterventional phase (754/801, 94.1%; p = 0.005). Intubation in the interventional phase showed decreases in the incidence of difficult laryngoscopy (12/308 [3.9%] v 157/801 [19.6%]; p < 0.001), as well as moderate or difficult intubation (5/308 [1.6%] v 57/801 [7.1%]; p < 0.001). The use of the McGrath videolaryngoscope as the first intubation option for tracheal intubation in cardiac surgery improves the percentage of patients with "easy" intubation," increasing glottic view and first-success-rate intubation and decreasing the incidence of moderate or difficult intubation.
Pharmacological interventions for chronic pain (CP) show limited evidence and adverse side effects, and thus, the management of CP represents a challenge for the healthcare systems. In the last few years, transcranial Electrical Stimulation (tES) has yielded positive results in relieving pain in patients with CP. However, the evidence has been obtained through group-level analyses without considering patient profiles that may benefit most from this technique. In this secondary analysis, we utilized data from a clinical trial involving 96 CP patients who undertook 15 daily consecutive sessions of tES at home of either transcranial Direct Current Stimulation or transcranial Alternate Current Stimulation. With the aim of ascertaining the predictors of treatment efficacy, we carried out a comparison between responders (patients with a pain intensity reduction of 30% or more after the tES treatment) and non-responders and built a multivariable binary logistic regression model. Only 24% of the patients reported a clinically significant improvement in pain intensity. Comparison between the clinical characteristics of patients showed that depression and anxiety-related variables appear to be the most closely related to treatment response. Moreover, finding signs that the number of years with depression and the onset of depression could be the variables with the highest (nearly significant) association with treatment response. These results provide preliminary clues to profile patients who could benefit more from tES, an important step to personalize neuromodulation treatments. Identifying CP patients who could benefit most from tES treatments could help clinicians with decision-making and reduce patient suffering through personalized treatments.